Journal of Otolaryngology-Head & Neck Surgery, published by SAGE Publications Inc, stands at the forefront of research in the fields of otorhinolaryngology and surgery. With an impressive Q1 ranking in both categories, this open-access journal, available since 2013, facilitates the dissemination of cutting-edge findings that enhance our understanding of complex head and neck disorders. Situated in the United Kingdom, the journal provides a vital platform for researchers, clinicians, and students to contribute to and engage with innovative therapeutic strategies and surgical techniques. The impact factor, underscored by its robust placement in Scopus rankings—7th among 123 in otorhinolaryngology and 35th among 551 in surgery—reflects its critical role in advancing evidence-based practice and informing clinical decisions globally. Covering a wide array of topics from basic science to practical implications, the journal is committed to fostering a collaborative and dynamic research environment.

Journal of Bone Oncology, published by ELSEVIER, is a pivotal open access journal that has been advancing the field of oncology since its inception in 2012. Focused on the intricate relationship between bone-related malignancies and therapeutic advancements, this journal addresses critical issues in bone oncology, including novel treatments, diagnostic methodologies, and translational research. With a commendable impact factor reflecting its scholarly contributions and ranking in the Q2 category of oncology journals (2023), the Journal of Bone Oncology is recognized within the top 67th percentile across Scopus rankings, showcasing its relevance and quality in the medical oncology landscape. Available in open access, the journal promotes widespread dissemination of knowledge, ensuring that researchers, professionals, and students can access groundbreaking research that informs clinical practices and enhances patient outcomes. Located in Germany and targeting a global audience, the journal’s wealth of resources serves as an essential platform for fostering collaboration and innovation in the oncology community.

Translational Gastroenterology and Hepatology, published by AME Publishing Company, stands as a pivotal platform for advancing the understanding and treatment of gastrointestinal and liver diseases. With its focus on translational research, this journal aims to bridge the gap between laboratory discoveries and clinical applications, thus fostering improvements in patient care. Although specific metrics like H-Index and Scopus ranks are currently unavailable, the journal is committed to maintaining high standards of scholarly communication and excellence. As an open-access publication, it ensures that valuable findings are readily accessible to a global audience, promoting collaboration and innovation among researchers, clinicians, and healthcare professionals invested in gastroenterology and hepatology. The journal's dedication to disseminating groundbreaking research makes it an essential resource for those seeking to stay at the forefront of these ever-evolving fields.

HemaSphere, published by WILEY, stands at the forefront of hematology research, offering a vital platform for the dissemination of cutting-edge findings in the field. Since its inception in 2017 and official transition to Open Access in 2018, the journal has positioned itself as a leading conduit for high-impact research, maintaining a prestigious Q1 quartile ranking in the Hematology category as of 2023. Addressed in the United States at 111 River St, Hoboken, NJ, HemaSphere aims to foster a global dialogue among researchers, clinicians, and students by providing unrestricted access to high-quality content that encompasses clinical and experimental advancements. With an array of engaging articles, reviews, and commentaries, HemaSphere contributes significantly to the advancement of hematology, ensuring that critical knowledge is readily accessible to enhance patient care and innovative research. To explore the latest developments and breakthroughs in this dynamic field, we invite scholars, professionals, and students to engage with HemaSphere and elevate their understanding of hematologic science.

Degenerative Neurological and Neuromuscular Disease is a distinguished academic journal published by DOVE MEDICAL PRESS LTD, focusing on the latest advancements in the field of neurology and neuromuscular disorders. With a commitment to disseminating high-quality research, the journal aims to provide a critical platform for researchers, healthcare professionals, and students to share and engage with groundbreaking studies that advance our understanding of degenerative conditions affecting the nervous system. Although the journal's impact factor and h-index are currently not available, its open access model ensures that the valuable findings published within are accessible to a global audience, thereby fostering collaboration and innovation in neurological health. The journal's address is PO BOX 300-008, Albany, Auckland 0752, New Zealand, reflecting its international relevance and commitment to advancing the field of neurology. As the understanding of neurodegenerative diseases and neuromuscular challenges continues to evolve, Degenerative Neurological and Neuromuscular Disease serves as an essential resource for anyone dedicated to improving patient outcomes and advancing scientific knowledge.

The Orphanet Journal of Rare Diseases, published by BMC since 2006, serves as a vital platform for the dissemination of groundbreaking research in the realm of rare diseases. With a notable Q1 ranking in both the Medicine (miscellaneous) and Pharmacology (medical) categories, and a respectable Q2 ranking in Genetics (clinical), the journal is recognized for its impactful contributions, evidenced by its position in the top quartiles of Scopus rankings. This open-access journal allows unrestricted access to its content, promoting a global exchange of knowledge among researchers, healthcare professionals, and academics. By covering a broad spectrum of rare diseases, the Orphanet Journal aims to enhance awareness, improve diagnosis and treatment, and ultimately contribute to the improvement of patients' lives. With a commitment to high-quality research, this journal stands as an essential resource for anyone involved in the study or treatment of rare diseases.

ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE is a distinguished journal that serves as a vital platform for disseminating innovative research and insightful reviews in the field of dermatology and venereology. Published by MASSON EDITEUR, this journal has been a cornerstone for professionals and researchers since its inception in 1977, offering a wealth of knowledge that spans decades. With its ISSN 0151-9638 and E-ISSN 2214-5451, it is indexed within leading databases, ensuring that the published work reaches a broad audience. The journal currently holds a Q3 ranking in the dermatology category, reflecting its commitment to quality and rigorous peer-review processes. While the journal is not open access, it provides an extensive archive of valuable studies that contribute to advancements in skin health and treatment methodologies. Located in Issy-les-Moulineaux, France, ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE continues to attract submissions from esteemed professionals, enhancing its reputation as a crucial resource for those dedicated to the ongoing development of dermatological sciences.

JOURNAL OF ENDOCRINOLOGY, established in 1946 and published by BIOSCIENTIFICA LTD, stands as a premier scholarly outlet in the field of endocrinology, diabetes, and metabolism. With an impressive H-Index reflecting its significant contribution to the literature, this journal maintains a strong presence in academic circles, evidenced by its Q1 ranking in the 2023 Scopus categories for both Endocrinology and Diabetes and Metabolism. With its targeted scope serving a global audience of researchers, professionals, and students, it provides a vital platform for disseminating innovative research findings and advancing the scientific understanding of endocrine systems. As we approach its convergence year of 2024, JOURNAL OF ENDOCRINOLOGY remains committed to publishing high-quality, peer-reviewed articles that explore cutting-edge developments in the field, thereby impacting clinical practices and guiding future research directions.

Discover Oncology, published by SPRINGER, is an influential journal based in Germany that focuses on the latest advancements in the fields of oncology and endocrinology. With an evolving scope that spans critical research from 2021 to 2024, this journal aims to provide a platform for innovative ideas and research findings that can significantly impact clinical practices. Although it currently holds a Q3 ranking in several Cancer Research and Endocrine category quartiles, its commitment to open access ensures that relevant knowledge is available to a wider audience, facilitating the exchange of ideas among researchers, professionals, and students. As evidenced by its growing presence in various medical spheres, including a Q2 ranking in Endocrinology and Diabetes, the journal plays a crucial role in advancing multidisciplinary research that integrates oncology with broader biological and medical parameters. For those in the field, Discover Oncology serves as both a resource and a community hub, encouraging collaboration and exploration of emerging findings that can lead to novel therapeutic approaches.

Therapeutic Advances in Neurological Disorders, published by SAGE Publications Ltd, is a leading open access journal dedicated to the advancement of knowledge in the field of neurology. Since its inception in 2008, this journal has established itself as a vital resource for researchers, healthcare professionals, and students, offering a platform for the dissemination of high-quality research that improves the understanding and treatment of neurological disorders. With a commendable impact factor and ranked Q1 in multiple categories, including Neurology and Pharmacology for 2023, it exemplifies excellence in scholarly contributions. The journal's Scope encompasses a wide array of topics, providing insights that are pivotal for clinical practice and pharmacological development. Additionally, with its commitment to open access since 2017, Therapeutic Advances in Neurological Disorders ensures that its research reaches a global audience, fostering collaboration and innovation in neurological science.